Meeting
2018 ASCO Annual Meeting
Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplification, HER2 mutation/amplification or HER3/4 mutation.
Authors
Sarina Anne Piha-Paul
The University of Texas MD Anderson Cancer Center, Houston, TX
Sarina Anne Piha-Paul , Siqing Fu , David S. Hong , Filip Janku , Daniel D. Karp , Aung Naing , Shubham Pant , Jordi Rodon Ahnert , Vivek Subbiah , Apostolia Maria Tsimberidou , Timothy Anthony Yap , Funda Meric-Bernstam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Other Novel Agents
Clinical Trial Registration Number
NCT03065387
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS2611)
DOI
10.1200/JCO.2018.36.15_suppl.TPS2611
Abstract #
TPS2611
Poster Bd #
429b
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results.
First Author: Aditya Bardia
Poster
2019 ASCO Annual Meeting
Single-arm, phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER2 exon 20 mutation.
First Author: Guanghui Gao
Poster
2019 ASCO Annual Meeting
Actionable coalterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
First Author: Arielle Lutterman Heeke
Poster
2017 ASCO Annual Meeting
Individualized screening trial of innovative glioblastoma therapy (INSIGhT).
First Author: Brian Michael Alexander